Stewart Grocery in Buffalo Gap closing after 8 decades of community service

BUFFALO GAP, Texas ()- Since 1946, Stewart Grocery in Buffalo Gap has been the local one stop shop for gassing up and chowing down, all the while owned and operated by the Stewart family. Owner Mickey Stewart announced recently that the store will be closing on Saturday, May 31, leading to an outpouring of memories and well wishes shared by locals.
Debbie Powers has been a store clerk at Stewart Grocery for about 5 years now, calling the place a 'home away from home', a sentiment that many in the community share. She tells KTAB/KRBC that the decision to close the store comes from a number of factors not the least of which are financial concerns due to the rising cost of stocking, insuring, and operating the beloved corner store.
Small Town Tales: Smithsonian Institute features Buffalo Gap in upcoming exhibit
'You have to have insurance on everything you sell out of the store to cover it. You have to have insurance on the property. That's went up probably 30, 40% over the last couple of years…it's kind of hard for a little mom and pops to compete with all the forward progress,' Powers said.
For all the bittersweet memories that have come up in the wake of the announcement, Powers hopes that the public will show up in force to say their farewells and buy their final goods throughout the coming week as their closing day approaches, Powers saying there is still time to make a few fond memories more.
'People come in and, you know, get a fountain drink visit. They always ask us how we're doing and we ask them how they're doing. I love that part. I'm going to miss that part of it…I myself am thankful for the community and their support and i know Mickey is thankful for it through the years. I would just say to them, don't be sad. Come out and give him a good sendoff. Help him clean the store out,' said Powers.
Cannonballs discovered in walls of historic courthouse in Buffalo Gap
Special deals on goods and store stock will be held all throughout the coming week leading up to the final day on Saturday, May 31. Powers saying that day will be the public's last chance to enjoy one of Mickey's famous ground meat hamburgers made from high quality chuck, as well as a slice of their well known pizza.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Wire

3 days ago

• Business Wire

Arialys Therapeutics Publishes Preclinical Data in Nature Communications Supporting ART5803 as a First-in-Class Precision Therapeutic for Anti-NMDA Receptor Autoimmune Neuropsychiatric Disease

LA JOLLA, Calif.--(BUSINESS WIRE)-- Arialys Therapeutics, a clinical-stage biotechnology company pioneering new precision medicines for autoimmune neuropsychiatric diseases, today announced the publication of preclinical data in Nature Communications demonstrating that its lead drug candidate, ART5803, effectively blocks the underlying disease mechanism in anti-NMDA receptor encephalitis (ANRE) and rapidly reverses behavioral symptoms in a non-human primate model. The findings support the continued clinical development of ART5803 as a first-in-class, targeted therapeutic. The company is currently completing Phase 1 safety studies for ART5803 and plans Phase 2 evaluation in anti-NMDA receptor encephalitis (ANRE) and autoimmune psychosis patients in the second half of 2025. 'This study underscores the promise of ART5803 to directly address neuropsychiatric disease caused by anti-NMDA receptor-targeting pathogenic antibodies,' said Peter Flynn, Ph.D. President and CEO of Arialys Therapeutics. Share 'This study underscores the promise of ART5803 to directly address neuropsychiatric disease caused by anti-NMDA receptor-targeting pathogenic antibodies,' said Peter Flynn, Ph.D. President and CEO of Arialys Therapeutics. 'Despite our understanding of the disease mechanism and its severity, ANRE lacks an approved therapy. Further, there is a growing body of data identifying significant levels of anti-NMDA receptor autoantibodies in subpopulations of patients diagnosed with diseases that result in psychosis and dementia.' 'These data provide compelling evidence that ART5803 can directly block the pathogenic effect of autoantibodies that target the NMDA receptor, resulting in a rapid resolution of symptoms,' said Mitsuyuki (Mickey) Matsumoto, Ph.D., Chief Scientific Officer of Arialys Therapeutics and senior author of the paper. 'Our detailed structural and functional analyses confirm that ART5803 precisely inhibits NMDA receptor internalization induced by the pathogenic autoantibodies, while preserving normal receptor function. In addition, our discovery of a potential molecular mimicry mechanism for anti-NMDA receptor autoantibody generation broadens the understanding of disease initiation and may inform future indication expansion for ART5803.' Anti-NMDA receptor encephalitis (ANRE) is a rare, potentially lethal, poorly managed, and often misdiagnosed neurological disease. ANRE is caused by pathogenic autoantibodies that bind to and crosslink NMDA receptors in the brain, leading to receptor internalization and synaptic dysfunction. The result is a range of debilitating neuropsychiatric symptoms including psychiatric and behavioral alterations, cognitive decline, seizures, coma, and diminished autonomic function. A significant percentage of ANRE patients are pediatric, where NMDA receptor-specific autoantibodies can also result in neurological development deficits. There are no approved therapies for this disease, and current treatments rely on broadly immunosuppressive therapies, which are associated with delayed efficacy and significant side effects. Recent findings have also identified anti-NMDA receptor autoantibodies in other neurological and psychiatric diseases such as schizophrenia, depression, bipolar disorder, and dementia. Arialys is planning clinical assessment of ART5803 in anti-NMDA receptor autoantibody-positive psychosis patients. The company is also currently testing patient samples using a proprietary high-throughput screen for autoantibodies to identify enriched disease indications and subpopulations for future clinical development. ART5803 is a humanized, monovalent IgG1 antibody engineered to selectively bind the GluN1 subunit of the NMDA receptor without disrupting receptor function or causing internalization. In this study, ART5803 demonstrated the ability to potently block NMDA receptor internalization in cellular and neuronal models and reversed both molecular and behavioral hallmarks of disease in a novel marmoset model of ANRE. Notably, ART5803 exhibited rapid onset of action and was well tolerated in vivo. The publication also includes a detailed characterization of ART5803's binding epitope, its mechanism of action, and population pharmacokinetic modeling supporting the feasibility of systemic administration in patients. In addition to demonstrating the therapeutic potential of ART5803, the paper revealed a potential link between infections—specifically Toxoplasma gondii and certain bacterial pathogens—and the generation of pathogenic anti-NMDA receptor autoantibodies. Epitope mapping analysis identified regions of potential molecular mimicry between microbial proteins and the GluN1 subunit of the NMDA receptor, suggesting that infections could serve as environmental triggers for disease initiation. Notably, toxoplasmosis and bacterial infections are well-established risk factors for a range of neuropsychiatric conditions. These findings not only suggest a basis for disease pathogenesis but also support broader therapeutic opportunities for ART5803 across autoimmune neuropsychiatric disorders. ART5803 is currently being evaluated in a Phase 1 clinical trial in healthy volunteers. In February 2025, Arialys announced completion of all single ascending dose (SAD) cohorts and initiation of multiple ascending dose (MAD) cohorts. The company expects to share initial clinical data in the second half of 2025 and initiate Phase 2 proof-of-concept studies. The publication was completed in collaboration with researchers from Astellas Pharma Inc., University of California, Davis, Kitasato University School of Medicine, and Vanadro LLC. About Arialys Therapeutics Arialys was founded by investors Avalon Bioventures, Catalys Pacific and MPM to meaningfully expand the treatment possibilities for neuropsychiatric disorders driven by autoimmune disease. Using a combination of highly sensitive autoantibody detection, patient sampling and receptor structural biology, Arialys has developed a first-in-class precision therapy to specifically block pathogenic autoantibodies in the brain. Arialys is headquartered in La Jolla, California. For more information, visit

Yahoo

11-06-2025

• Yahoo

Bob Iger Says Disney Unlikely to Follow Comcast and Warner Bros. Discovery In Exiting the TV Channel Business

Will Disney follow Warner Bros. Discovery and Comcast in splitting off most of its TV assets from its streaming business? Don't bet on it. CEO Bob Iger appeared on CNBC Tuesday morning, where he was interviewed by David Faber about his company's acquisition of Comcast's share in Hulu, which was finalized Monday. More from The Hollywood Reporter Disney's House of Mouse Global Tour Debuts New Mickey & Friends Collabs and Disneyland Anniversary Merch in L.A. (Exclusive) Disney+ Inks New Deal to Bundle With Crave, TSN in Canada Inside Hollywood's Succession Wars But Faber also used the opportunity to ask whether Iger, who effectively kickstarted the idea of splitting linear TV from streaming in a CNBC interview two years ago, whether Disney is reevaluating its decision to keep its company together. Warner Bros. Discovery said Monday that it would split itself in two: One company with the studios and HBO Max streaming business, and another with its global TV networks. That move followed a similar decision from Comcast, which is spinning out most of its cable channels into Versant later this year, but keeping NBC, Bravo, Peacock and theme parks for itself. 'Soon after I returned to Disney, I put everything on the table and asked the team to evaluate whether we should buy Hulu or whether we should sell Hulu, whether we should sell our linear television networks or whether we should hold on to them, and after a pretty lengthy process internally, and really taking a long look at what these properties could mean to us, long term, we decided that the best course for us to take was to not only buy [Hulu] in its entirety, but also to hold on to the linear television networks and to integrate them seamlessly with our streaming business,' Iger said. 'What that has enabled us to do is aggregate revenue, both on the sub fee side and on the advertising side. There is still enough linear television subscribers to generate a significant amount of revenue in advertising and in subscription fees. We program them seamlessly, we manage them in one organization. And so there's been great economies of scale in doing that.' 'It's one of the things that's enabled us to turn the streaming business around from a huge loss to profitability, and over the next several years, it will enable us to grow margins significantly on the streaming side, because of the ability to amortize program costs and the ability to essentially aggregate audiences in revenue,' he added. 'It's also interesting to us that as many others exit that business, I think it gives us a stronger hand to stay in that business. We're very focused. We will have, interestingly enough, a linear television business that's paired with a streaming business. So when you think about it, these spin off companies won't have the assets from a streaming perspective that we will have.' And having a broadcast network like ABC is a big part of that. 'I think there's a lot more value in a broadcast network, again, if it's paired very, very seamlessly with a streaming business,' Iger said. 'I mean, you think about our core networks, obviously, ESPN is a big one. That will be connected, obviously, fully with ESPN's digital offering. Disney Channel is connected seamlessly with Disney Plus. FX and ABC have fed Hulu programming very effectively. And now when you think about all four, and we also have Nat Geo, which does the same with Disney Plus, when you think about those five networks and how they're programmed across linear and streaming, you've got a business that actually provides us an opportunity to not only grow, but to grow margins in the process as well. So, again, we like the direction we're going. We like the fact that we're one of the few that is doing this, because I think it sets us up to be even more competitive in a marketplace that's becoming even more fragmented.' Iger also said that Disney+ will most likely follow the path laid by Netflix, which stopped reporting its subscriber numbers on a quarterly basis. 'Probably,' Iger said, when asked by Faber if the company will pursue that strategy. 'We're focused on EBITDA and cash flow and growing margins, and that's, in fact, what we're doing. I think at some point, what we're mostly going to disclose is the bottom line.' Best of The Hollywood Reporter How the Warner Brothers Got Their Film Business Started Meet the World Builders: Hollywood's Top Physical Production Executives of 2023 Men in Blazers, Hollywood's Favorite Soccer Podcast, Aims for a Global Empire

Yahoo

09-06-2025

• Yahoo

James Hardie Industries plc (JHX): A Bull Case Theory

We came across a bullish thesis on James Hardie Industries plc (JHX) on Directionally Correct Research's Substack by Will Powers. In this article, we will summarize the bulls' thesis on JHX. James Hardie Industries plc (JHX)'s share was trading at $25.76 as of 6th June. JHX's trailing and forward P/E were 26.29 and 21.51 respectively according to Yahoo Finance. Aerial view of a suburban home under construction, displaying its modern architecture. James Hardie's proposed acquisition of AZEK is a bold, potentially transformative deal that brings together two leading exterior building products: high-performance fiber cement siding and backerboard. Management forecasts $500M in commercial synergies by FY26, implying a $225M EBITDA contribution at 45% margins. But realization is far from guaranteed. Both companies rely on two-step distribution, and success hinges on distributors' willingness and ability to push a broader, bulkier product suite. Siding and decking, while adjacent categories, lack natural bundling—there's no compelling homeowner rationale to undertake both upgrades simultaneously. Execution risk from integrating two independent sales forces further tempers optimism. Yet, if even half the synergies materialize, they still provide a meaningful uplift. Valuation assumes a conservative synergy haircut, normalized R&R growth, and stable pricing to drive ~10% top-line growth through FY28. Margins expand as volume leverage kicks in, with Hardie's North American EBITDA reaching 39% and AZEK hitting its 27.5% goal. Combined EBITDA surpasses $2.1B by FY28, with FCF conversion improving into the high 40s. A base 13.5x multiple implies a $44 share price and low-20s IRR; a rerating to 15x lifts it to $50. The deal's timing—amid change-in-control incentives and before an NYSE relisting—raises questions of insider motivations and execution risk. While the price tag looks steep and macro headwinds remain a threat to these discretionary categories, JHX remains a well-run compounder with expanding margins, strong cash generation, and potential index inclusion tailwinds. Investors willing to stomach integration risk and cyclicality may find value in what could be trough earnings and sentiment. Previously, we covered a by Will Powers in December 2024, highlighting its dominant position in fertility benefits, resilient cash flow, and post-Amazon client loss recovery. The stock has appreciated by approximately 47%. Powers frames PGNY as a cash-rich recovery play and JHX as a margin-expansion story with integration risk, offering distinct but complementary opportunities rooted in long-term structural growth. James Hardie Industries plc (JHX) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 12 hedge fund portfolios held JHX at the end of the first quarter which was 5 in the previous quarter. While we acknowledge the risk and potential of JHX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data